Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

MCC > Wk 7 Natural Chemotherapy Agents > Flashcards

Wk 7 Natural Chemotherapy Agents Flashcards

1
Q

Name of 2 topoisomerase I inhibitor

A

Irinotecan
Topotecan

-both are Camptothecins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2 Topoisomerase II inhibitors

A
  1. Doxorubicin (an anthracycline)
  2. Etoposide (an epipodophyllotoxin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Microtubular targeting agents

A

Vincristine - a vinca alkaloid
Paclitaxel - a taxane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antibiotic chemotherapy

A

Bleomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Selective estrogen receptor modulator

A

Tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

LHRH agonist

A

Goserelin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the ABCDEs of melanoma?

A

A = asymmetry
B = border
C = color
D = diameter
E = evolution (melanomas change rapidly, nevi usually don’t)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is a nevi?

A

a neoplasm that’s usually benign
-increase risk of melanoma
-common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are tx options for malignant melanoma?

A

Immunotherapy: anti-CTLA4, anti-PD1
BRAF inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Melanoma Risk Factors

A

-lighter pigmentation, sunburns at young age, more UV exposure
-worse melanoma-specific survival w/ African ancestry
-p16 loss (encoded at CDKN2A)
-spontaneous melanoma w/ BRAF-activating mutations (others: NRAS, KIT, TERT promotor mutations)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of Topoisomerase I inhibitors

A

Topoisomerase I relaxes supercoiled dsDNA
-inhibitors bind DNA and topo I together until the DNA replication fork reaches the cleavable complex and causes dsDNA breaks

-S-phase specific

-resistance can occur from mutations in topo I, decreased intracellular retention or reduced [topo I]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA Irinotecan

A

AKA SN-38
-is a prodrug
-activated by carboxylesterdase in tissues and serum
-glucuronidation = breakdown pathway
-need to check for genetic polymorphism b/c can be highly toxic w/ breakdown pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Irinotecan Tox

A

Diarrhea
-neutropenia, mucositis, N/V, alopecia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA Topo II inhibitors

A

-Topo II unwinds supercoiled dsDNA
-inhibitors bind DNA and topo II together, making transient cleavable complexes continually cleavable, preventing re-ligation

-S-phase sensitive
-Resistance due to p-glycoprotein upregulation, increase in drug degradation, or decreased [topo II]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Etoposide

A

AKA VP-16
IV/PO
-hepatic metabolism
-renal excretion

AE: myelosuppression, delayed secondary malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Anthracycline (Doxorubicin) MOA

A

Intercalates w/ DNA, interferes w/ uncoiling:
-interferes w/ topo II preventing strand reconnection
-intercalation alters shape, impairing repair enzymes
-forms free radicals ->cell structure damage

-Resistance due to P-glycoprotein, alteration of topo fxn, or decreased topo II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Doxorubicin AE, route

A

IV
-hepatic elimination
-cardiotoxicity (acute & chronic - lifetime exposure can -> CHF)
-myelosuppression, mucositis, extravasation necrosis, alopecia, emesis
-red urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What med acts as a heart protectant for anthracyclines?

A

Dexrazoxane
-chelates iron in the heart (necessary for free radical damage)
-not ideal b/c takes 1 of 3 MOAs from the anthracyclines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the 2 classes of microtubule targeting agents?

A
  1. Vinca alkaloids (know Vincristine)
  2. Taxanes (know Paclitaxel)

-both natural products from plants & trees

20
Q

MOA Vincristine

A

Bind to tubulin PREVENTING microtubule assembly

-spindle poisons, arresting cells in mitosis

21
Q

MOA Paclitaxel

A

binds to tubulin PROMOTING assembly into microtubules while simultaneously INHIBITING disassembly

-spindle poisons, arresting cells in mitosis

22
Q

When would Vincristine be fatal?

A

If given intrathecally

23
Q

Vincristine Tox

A
  1. neurotoxicity - peripheral neuropathy, autonomic neuropathy -> constipation
  2. minimal myelosuppression, SIADH, alopecia
24
Q

Paclitaxel Tox

A

Myelosuppression, peripheral sensory neuropathies
-hypersensitivity rxn
-alopecia, bradycardia, myalgias

25
Natural antibiotic chemotherapy drug
Bleomycin
26
Bleomycin MOA
has DNA & metal binding region, which allow it to cause DNA breaks by free radical damage in G2
27
Bleomycin Tox
-lung fibrosis, skin marks (b/c don't have bleomycin hydrolase in lungs or skin to break it down) -minimal myelosuppression
28
Bleomycin resistance
Increased DNA repair Increases bleomycin hydrolase
29
When is bleomycin used?
Testicular cancer Hodgkin Lymphoma
30
What are 2 drug categories under endocrine therapies?
1. Antiestrogens 2. aromatse inhibitors
31
What is a SERM?
Selective estrogen receptor modulator -Tamoxifen
32
Tamoxifen MOA
=estrogen antagonist -reversibly binds ER receptor on breast cancer cells -> RNA transcription is impaired =pro-estrogenic (agonist) in uterus (endometrial cancer) and bone (preserves bone density) -use in pre-menopausal
33
Aromatase inhibitor MOA
Aromatase converts androgens to estrogen -selective, irreversible binding to prevent production of estrogen -structurally related to androstenedione -use in post-menopausal
34
Tamoxifen pharmacokinetics
oral -a prodrug, converted to active metabolite (endoxofen) by liver via CYP2D6 -CYP2D6 interactions (SSRIs)
35
Tamoxifen AEs
-> post-menopausal state and menopausal symptoms: hot flashes, nausea, fatigue -endometrial carcinoma -DVTs/PEs -prevention of postmenopausal bone loss
36
Aromatase inhibitor AEs
-> menopausal symptoms: sweating, fatigue, hot flashes, flu-like symptoms -myalgia -N/V -decreased bone density
37
What is Goserelin
An LHRH agonist
38
Describe the hormonal regulation of androgens
39
Goserelin (and other LHRH agonist) MOA
Suppresses pituitary gonadotropin release of LH and FSH by downregulating the LH receptors (a negative feedback inhibition) -> initial surge of LH and FSH -> tumor flare from increased androgen synthesis (related to first doses and pulse dosing) -continual dosing -> pituitary receptor down regulation and functional antagonism
40
LHRH Agonist AEs
Hot flashes erectile impotence decreased libido injection-site reactions
41
LHRH Antagonist MOA
bind reversibly to pituitary GnRH receptors reducing release of androgens -no tumor flare since antagonist -Degarelix subcutaneous
42
Antiandrogen MOA
Competitive inhibitor of androgen receptors preventing androgen receptor activation
43
Antiandrogen AEs
-gynecomastia -hot flashes -diarrhea -LFT abnormalities - monitor
44
What 2 agents require monitoring with LVEF?
1. Doxorubicin 2. Trastuzumab
45
Tumor Lysis Syndrome (TLS)
Caused by massive tumor cell ylsis and release of intracellular -Allopurinol - decreased formation of uric acid. AEs - rash -Rasburicase - rapid uric acid reduction by catalyzing oxidation
46
LHRH Agonist Surge Effect
Flare (cancer SE) and intentional LH/FSH stimulations (fertility use in non-cancer) are related to first doses and pulse dosing -continual dosing leads to pituitary receptor down regulation and functional antagonism

MCC (44 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions